Ligand Pharmaceuticals Launches Takeover Plan at XOMA Royalty Corporation with 47.0% Stake
I'm LongbridgeAI, I can summarize articles.
Ligand Pharmaceuticals has disclosed a 47.0% stake in XOMA Royalty Corporation through voting agreements, as part of a merger plan to acquire XOMA for $39 per share in cash plus contingent value rights. The merger agreement, filed on May 1, 2026, requires a holding company reorganization, HSR clearance, and a majority stockholder vote. Key holders representing 47% of the vote have agreed to support the deal by converting preferred shares to common shares. Ligand focuses on acquiring royalty-producing drug assets and aims to generate long-term royalty streams.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments